Combined analysis of metabolomics and 16S rRNA sequencing for ankylosing spondylitis patients before and after secukinumab therapy
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.15218 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Chao Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing, Gastrointestinal Microbiome, Antibodies, Monoclonal, Humanized, Feces. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Natural Science Research Project of Anhui Educational Committee.
Abstract (Originalsprache)
Objective
Alterations in gut microbiota have been implicated in the pathogenesis of ankylosing spondylitis (AS), but the underlying mechanisms remain elusive. This study aims to investigate changes in gut microbiota and metabolites in individuals with AS before and after treatment with secukinumab, to identify the biological characteristics specific to AS patients and investigate the potential biomarkers, for optimizing therapeutic strategies more effectively.
Methods
Fecal microbiome data were collected from 30 AS patients before and after secukinumab therapy and compared with data from 40 healthy controls (HC). Additionally, we analyzed the metabolic profile of both groups from plasma.
Results
Findings indicated that the treatment‐induced changes in the composition of several crucial bacterial groups, including Megamonas , Prevotella_9 , Faecalibacterium , Roseburia , Bacteroides , and Agathobacter . Post‐treatment, these groups exhibited a distribution more akin to that of the healthy populations compared with their pretreatment status. We identified three gut microbial taxa, namely Prevotellaceae_bacterium_Marseille_P2831 , Prevotella_buccae , and Elusimicrobiota , as potential biomarkers for diagnosing individuals at a higher risk of developing AS and assessing disease outcomes. Plasma metabolomics analysis revealed 479 distinct metabolites and highlighted three disrupted metabolic pathways. Integration of microbiome and metabolomics datasets demonstrated a significant degree of correlation, underscoring the impact of the microbiome on metabolic activity.
Conclusion
Secukinumab can restore the balance of the gut microbiome and metabolites in AS patients, rendering them more similar to those found in the healthy population. The analysis of microbiome and metabolomics data have unveiled some candidate biomarkers capable of evaluating treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
- Anhui Province Key Laboratory of Immunology in Chronic Diseases, Bengbu Medical University, Bengbu, China.
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-Related Diseases, Bengbu, China.
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.
- Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
- Department of Orthopedics, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
ORCID-Profile: Haojie Xu
Förderung
- Natural Science Research Project of Anhui Educational Committee
Zitieren
APA
Sun, C., Chao, Y., Xu, H., Yang, X., Pei, L., Xu, G., Wang, F., Fan, X., Tang, L., Xie, C., Su, Y., & Wang, X. (2024). Combined analysis of metabolomics and 16S rRNA sequencing for ankylosing spondylitis patients before and after secukinumab therapy. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15218
Vancouver
Sun C, Chao Y, Xu H, Yang X, Pei L, Xu G, et al. Combined analysis of metabolomics and 16S rRNA sequencing for ankylosing spondylitis patients before and after secukinumab therapy. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15218
BibTeX
@article{Sun2024,
author = {Sun, Chao and Chao, Yuyan and Xu, Haojie and Yang, Xinmeng and Pei, Lijia and Xu, Guixia and Wang, Fei and Fan, Xiaoyun and Tang, Lin and Xie, Changhao and Su, Yin and Wang, Xin},
title = {Combined analysis of metabolomics and 16S rRNA sequencing for ankylosing spondylitis patients before and after secukinumab therapy},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.15218}
}
EUVIMED